Quantcast FDA Approvals FDA Approvals

​FDA Approvals

 

 

Groundbreaking New Immunotherapy Approved for Acute Lymphoblastic Leukemia (ALL)14171The U.S. Food and Drug Administration has approved the first of a new type of immunotherapy called CAR T–cell therapy for ALL.9/8/2017 6:32:58 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709009_Tcelltherapy_150x190_1.jpg" style="BORDER&#58;0px solid;" />Groundbreaking New Immunotherapy Approved for Acute Lymphoblastic Leukemia (ALL)The U.S. Food and Drug Administration has approved the first of a new type of immunotherapy called CAR T–cell therapy for ALL.47
Targeting Adult Acute Lymphoblastic Leukemia1272The FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL.9/19/2017 3:20:47 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709008_Ozogamicin_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Adult Acute Lymphoblastic LeukemiaThe FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL.51
FDA Approves a New Treatment for Acute Myeloid Leukemia17009The new treatment, Vyxeos, comprises a combination of two commonly used cytotoxic chemotherapeutics inside a nanosized particle.9/14/2017 7:54:37 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709011_Vyzeos_150x190_1.jpg" style="BORDER&#58;0px solid;" />FDA Approves a New Treatment for Acute Myeloid LeukemiaThe new treatment, Vyxeos, comprises a combination of two commonly used cytotoxic chemotherapeutics inside a nanosized particle.50
Targeting Acute Myeloid Leukemia16838Enasidenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months.9/12/2017 4:36:17 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709010_Enasidenib_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Acute Myeloid LeukemiaEnsadenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months. 49
Expanding the Use of an Immunotherapeutic to Colorectal Cancer15999The FDA decision means the immune checkpoint inhibitor nivolumab is now approved for seven types of cancer.9/8/2017 7:03:45 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709007_Nivolumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding the Use of an Immunotherapeutic to Colorectal CancerThe FDA decision means the immune checkpoint inhibitor nivolumab is now approved for seven types of cancer. 48
Targeting HER2-positive Breast Cancer4477The FDA has approved a new HER2-targeted therapeutic for the treatment of certain patients with early-stage breast cancer.7/24/2017 7:28:56 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1707042_HER2pos_Headshot_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting HER2-positive Breast CancerThe FDA has approved a new HER2-targeted therapeutic for the treatment of certain patients with early-stage breast cancer.46
Immunotherapeutic Use Expanded to Bladder Cancer909The FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer.6/21/2017 2:00:21 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706008_Pembrolizumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Use Expanded to Bladder CancerThe FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer.45
Immunotherapeutic Use Expanded to Bladder Cancer8730This is Cancer Progress Report The FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer.6/21/2017 2:00:21 PMhttp://vmcsp1301:8201/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706008_Pembrolizumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Immunotherapeutic Use Expanded to Bladder CancerThe FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer.45
Targeting Tumors Based on a Biomarker3727The FDA’s new approval for the immunotherapeutic pembrolizumab is the first based entirely on a tumor biomarker rather than the site where the cancer originated.6/19/2017 8:32:38 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706007_PembroBio_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Tumors Based on a BiomarkerThe FDA’s new approval for the immunotherapeutic pembrolizumab is the first based entirely on a tumor biomarker rather than the site where the cancer originated.44
Another Immunotherapy Approved for Bladder Cancer3705Avelumab is the fourth immune checkpoint inhibitor to get FDA approval to treat certain patients with bladder cancer.6/19/2017 6:47:03 PMhttps://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1706010_Avelumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Another Immunotherapy Approved for Bladder CancerAvelumab is the fourth immune checkpoint inhibitor to get FDA approval to treat certain patients with bladder cancer. 43

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300